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Abstract 
Background 
Prognostic factors are associated with the risk of future health outcomes in individuals with a 
particular health condition. The prognostic ability of such factors is increasingly being 
assessed in both primary research and systematic reviews. Systematic review methodology in 
this area is continuing to evolve, reflected in variable approaches to key methodological 
aspects. The aim of this article was to (i) explore and compare the methodology of systematic 
reviews of prognostic factors undertaken for the same clinical question, (ii) to discuss 
implications for review findings, and (iii) to present recommendations on what might be 
considered to be ‘good practice’ approaches. 
Methods 
The sample was comprised of eight systematic reviews addressing the same clinical question, 
namely whether ‘aspirin resistance’ (a potential prognostic factor) has prognostic utility 
relative to future vascular events in patients on aspirin therapy for secondary prevention. A 
detailed comparison of methods around study identification, study selection, quality 
assessment, approaches to analysis, and reporting of findings was undertaken and the 
implications discussed. These were summarised into key considerations that may be 
transferable to future systematic reviews of prognostic factors. 
Results 
Across systematic reviews addressing the same clinical question, there were considerable 
differences in the numbers of studies identified and overlap between included studies, which 
could only partially be explained by different study eligibility criteria. Incomplete reporting 
and differences in terminology within primary studies hampered study identification and 
selection process across reviews. Quality assessment was highly variable and only one 
systematic review considered a checklist for studies of prognostic questions. There was 
inconsistency between reviews in approaches towards analysis, synthesis, addressing 
heterogeneity and reporting of results. 
Conclusions 
Different methodological approaches may ultimately affect the findings and interpretation of 
systematic reviews of prognostic research, with implications for clinical decision-making. 
Systematic review registration 
This review of systematic reviews in one medical area has been used to generate a number of 
recommendations for those undertaking systematic reviews of prognostic research; these 
include a step-wise hierarchical approach to study selection and suggested approaches for 
analysis (e.g. maximisation of data for meta-analysis). This work adds to and extends the 
growing body of methodological evidence in this field. 
Keywords 
Systematic review methodology, Prognostic utility, Prognostic factor, Aspirin resistance, 
Cardiovascular disease, Search strategy, Study selection, Quality assessment, Reporting bias 
Background 
Prognosis research is becoming increasingly important in health care, with a greater number 
of people than ever before living with chronic disease [1]. Prognostic factors relate to any 
measures that are associated with the risk of future health outcomes in individuals with a 
particular health condition [2]. Identification of prognostic factors can be potentially useful 
for informing a patient’s risk profile and for making therapeutic decisions [2]. The poor 
quality of prognostic research is however well documented, with issues relating to study 
design (e.g. retrospective rather than prospective), reporting (e.g. inconsistent use of 
nomenclature relating to prognostic research) and publication bias (e.g. preferential 
publication of articles with positive findings); this in turn impacts on the quality of systematic 
reviews and meta-analyses of published prognostic studies, which may be limited or biased in 
their conclusions [2,3]. 
There are no accepted guidelines for undertaking systematic reviews of prognosis, and 
methodology is still evolving. Some methodological recommendations have been proposed 
by Hayden et al. [4] based on an evaluation of systematic reviews of low back pain prognosis. 
Recommendations include, amongst others, the assessment of all important potential biases 
and testing of the impact of specific biases on the review conclusions; listing studies where 
eligibility criteria may be unclear; and the use of sub-group and sensitivity analyses to 
explore sources of heterogeneity. Some recommendations for conducting systematic reviews 
of prognostic tests have also been made by the US Agency for Healthcare Research and 
Quality (AHRQ) [5] relating to, for example, defining the review question, searching, 
specific quality criteria to be used and extraction of summary statistics. 
The Cochrane Prognosis Methods Group [6] acts as a repository for publications of prognosis 
methodology. It also offers advice to review authors on incorporating prognosis information 
into their reviews and to establish methods for undertaking systematic reviews and meta-
analyses of prognosis studies; a chapter about reviews of prognosis for inclusion into the 
Cochrane Handbook is planned but as yet there are no specific guidelines. 
Guidelines on data extraction and critical appraisal of risk prediction model studies have 
recently been published [7], and it is likely that some issues may overlap with prognostic 
studies. 
This article explores the methodology of systematic reviews of prognosis in a cardiovascular 
area. The clinical question related to the prognostic utility of platelet function tests (PFT) for 
the detection of ‘aspirin resistance’ in patients with established cardiovascular or 
cerebrovascular disease; more specifically, whether insufficient platelet function inhibition by 
aspirin (‘aspirin resistance’) as defined using one of several PFTs was associated with an 
increased risk of adverse clinical outcomes. A further aim was to identify whether individual 
patients at greater risk of future adverse clinical events could be identified through PFTs. In 
this example, the prognostic factor (‘aspirin resistance’) is defined by the result of a clinical 
(diagnostic) test result (i.e. an individual is designated as ‘aspirin resistant’ or ‘aspirin 
sensitive’ using a PFT), so either ‘aspirin resistance’ or the PFT result could be considered to 
be the prognostic factor, as they are both describing a state of platelet reactivity. 
A ‘systematic review of systematic reviews’ was undertaken as part of a wider project, which 
comprised a new systematic review on the same topic and an economic evaluation [8,9]. Both 
the new systematic review and the previous systematic reviews are used as illustrative 
examples throughout. The aim of this article was not to critique individual reviews but to 
explore and compare the different methodological approaches employed within these 
reviews, examine whether different methodological approaches can affect overall findings 
and conclusions drawn, and draw out common methodological considerations which may be 
useful for informing future systematic reviews of prognostic factors. 
Methods 
The search for systematic reviews [9] was performed in April 2012 and updated in May 2014 
(see Additional file 1 for sample search strategy). Systematic reviews were eligible for 
inclusion if their primary aim was to examine or quantify the potential association between 
‘aspirin resistance’ (a candidate prognostic factor, which is defined by a PFT) and risk of 
future cardiovascular events in patients who were prescribed aspirin therapy. Further 
inclusion criteria were as follows: reporting of search strategy and at least one other 
methodological component (e.g. details on study selection process or quality assessment) and 
all types of PFT eligible (i.e. reviews focussing on only one specific PFT were excluded). 
The following components of the reviews were then compared and key differences tabulated 
(where reporting allowed): 
• Volume of evidence 
• Search strategy 
• Eligibility criteria 
• Quality assessment strategy 
• Reporting of results. 
Potential impacts on findings and implications for future systematic reviews of prognostic 
factors were discussed. 
In a separate exercise, and in order to further explore different approaches to search 
strategies, different validated prognostic search filters were also added to the original search 
strategy of one systematic review [8] in order to assess the effect on sensitivity and precision 
of the search. 
Results 
Eight relevant systematic reviews were identified, with publication dates from 2007 to 2014 
(see Additional file 2 for review selection process and characteristics of systematic reviews): 
seven [10-16] through the searches and the HTA report/new systematic review [8] itself. All 
eight systematic reviews had the same aim, namely to explore the association between 
‘aspirin resistance’ and the risk of future cardiovascular events in patients on aspirin therapy 
for secondary prevention. 
Volume of included studies and method of determination of prognostic factor 
(platelet function test) 
The number of included primary studies and the consistency between the eight reviews were 
explored. Primary studies with a publication date up to 2006 were considered, in order to 
make the search periods comparable across reviews. Thirty-eight unique studies were 
included across these reviews for this period. The numbers of studies included in individual 
reviews varied between 2 and 25 for the time period up to 2006 (see Additional file 3 for 
number and overlap between reviews). No study was included in all eight systematic reviews. 
Only four studies were consistently represented in 7/8 (88%) of the systematic reviews, six 
studies in ≥75% of the reviews, nine studies in ≥63%, 14 studies in ≥50%, with the remainder 
of primary studies (n = 24) represented in only 1–3 of the eight reviews. The prognostic 
factor can be measured by a number of different methods (PFTs), and no review restricted 
inclusion to a specific PFT. As a consequence of including different primary studies, varying 
proportions of studies using a particular method (PFT) were represented in the eight reviews 
(Figure in Additional file 4). Different inclusion criteria unrelated to the type of PFT are 
thought to have contributed to these discrepancies to some extent and are further discussed 
below. The systematic review by Li et al. [15], for example, included only studies where 
compliance had been verified. However, it does not appear that differing selection criteria 
explain all of the considerable variation. Reliably identifying prognostic studies continues to 
be a problem in systematic reviews of prognostic factors. 
Search strategies 
Search strategies, in particular with regard to filters for study identification, are less well 
developed in the prognosis field and potentially less able to identify relevant studies [17]. 
This appears to be reflected within this example in the number and type of search terms, as 
well as combinations of terms, which varied substantially between the reviews. Table 1 
shows the types of search terms included in the respective search strategies. None of the 
reviews reported use of a filter for prognostic studies, though the HTA report [8] incorporated 
search terms relating to prediction and prognosis. There were similarities in terms of sources 
searched, with all searching at least two major electronic databases (such as MEDLINE, 
Embase, the Cochrane library) and using citation checking. Where studies specified the initial 
number of citations identified with their search strategy, the numbers varied greatly: 36,573 
[11], 16,583 [8], 3,847 [15], 3,882 [16] and 1,978 [13], a reflection of the sensitivity 
(breadth) of the initial search. Two reviews [10,11] attempted to reduce the number of hits by 
subsequently including additional limits. The initial search yield did not necessarily appear to 
correlate with a greater number of included studies; however, a formal assessment of this 
across reviews was not possible due to a lack of clarity in the reporting of yields at different 
stages. 
Table 1 Search terms used in the systematic reviews 
Search terms relating to Systematic reviews* 
HTA report [8] Li et al. [15] Pusch et al. [12] Sofi et al. [14] Krasopoulos et al. [11] Wisman et al. [16]+ Canivano and Garcia [10] 
Aspirin 
✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Resistance 
✓ ✓ ✓ ✓ ✓ ✓ ✓ 
Platelet (function) 
✓ ✓ ✓ ✓ ✓ ✓ 
 
Outcomes/condition 
✓ ✓ ✓ ✓ 
   
Names of PFTs 
✓ 
      
Prognosis/prediction 
✓ 
      
Filter for study design        
*Search terms not listed in the systematic review by Snoep et al. [13]. +Not clear if all search terms listed. 
In order to test whether the introduction of a prognostic filter could have limited the 
sensitivity (and reduced the number of hits), whilst retaining the precision (i.e. identify 
relevant studies), the literature searches for the HTA report [8] were rerun, for MEDLINE 
only, with additional validated Haynes filters relating to prognosis and clinical prediction 
[17]. It was found that the ‘prognosis’ Haynes filter picked up 77% of studies identified by 
the original broader search strategy whilst reducing the volume of overall hits to 82%; the 
‘clinical prediction guide’ Haynes filter picked up 62% of studies, whilst reducing the volume 
to 72%. These results show that studies meeting the eligibility criteria would have been 
missed using either of the prognosis/prediction filters, though they both significantly reduced 
the larger initial quantity of evidence. In the current context, it is unlikely that citation 
checking (forward and backward) would have led to the identification of the missed studies, 
but this remains to be empirically tested. 
Inclusion criteria 
There were variations between reviews both in the level of reporting of inclusion and 
exclusion criteria and the actual criteria applied. Only three reviews [8,11,16] gave details on 
whether patients who were receiving aspirin as monotherapy and/or dual therapy (aspirin + 
other antiplatelet agent) were eligible; this distinction is important as the presence of a second 
antiplatelet agent may interact with the prognostic factor assessment (platelet function) and 
also be associated with the outcome of interest (cardiovascular events). 
Further, only 5/8 [8,11,14-16] reviews specified whether prospective and/or retrospective 
study designs were eligible. Both concomitant therapy and study design are factors that may 
have an effect on results, and if not specified, may introduce bias into overall findings. 
Further, the terms prospective or retrospective may be used to describe the study design but 
may not apply in the same way to data collection/analysis. For example, sample collection 
may have occurred before the outcome of interest, but analysis of the sample (i.e. 
measurement of the prognostic factor by PFT) may have been undertaken after the outcomes 
occurred. One such example is the study by Eikelboom et al. [18], which is described as a 
nested case–control study (within an RCT) but could also meet the criteria for a prospective 
(prognostic) study as sample collection preceded clinical events. 
Other eligibility criteria variously specified in individual reviews only were the reporting of 
specific outcome statistics [14], blinding of investigators [11] measurement of patient 
compliance [15] or English language [16]. Again, these criteria may have an impact on 
completeness and robustness of the evidence identified and synthesised by each review. 
Regardless of how eligibility criteria have been defined, screening for eligibility may be 
hampered by poor reporting. The HTA report [8] found that the levels of reporting within 
primary studies varied dramatically in terms of whether (i) the results of the PFT (for 
assessment of prognostic factor) were reported, (ii) results were dichotomized (‘resistant’ and 
‘sensitive’), (iii) cardiovascular outcomes were reported, and (iv) outcomes were linked to 
‘resistant’ and ‘sensitive’ groups. Not all of this information was necessarily discernable from 
the abstract, thus necessitating a detailed reading of whole articles at an early screening stage. 
Differences in selection criteria can lead to different included studies, and as a result, 
different conclusions as to the prognostic utility of a factor of interest. Even where included, 
studies are consistent across reviews, the quality of reporting within included studies may 
also influence any conclusions drawn by review authors. 
Quality assessment of included studies 
Quality assessment of primary prognostic studies is a developing field, and the different 
approaches used across the eight reviews may in part be a reflection of their publication date. 
Both quality assessment (where undertaken) and use of quality findings in interpreting results 
were highly variable within this example (see Table 2). Three reviews used an item related to 
study quality as an eligibility criterion, e.g. ‘investigators blinded to patients’ aspirin status’ 
[11] which is in contrast to effectiveness questions where quality assessment can, but does 
not usually, form part of the study selection process. This may be problematic where such 
quality items have not been reported in the article. 
Table 2 Quality assessment approaches 
Review Quality assessment undertaken and method Findings presented/use of summary score Findings used in context of  
results/sensitivity analysis 
Comment 
Canivano and Gracia [10] None N/A N/A  
HTA report [8] Quality assessment tool derived from QUADAS 
[19] and the Hayden checklist relating to 
prognostic studies [20] 
Results of the quality assessment were 
presented 
Impact commented on but sensitivity analyses 
not deemed possible. 
 
Krasopoulos et al. [11] Study eligibility criterion: investigators to be 
blinded to patients’ aspirin status 
Quality rating for risk of bias (A to D) but not 
explicit on how this was derived 
No Terminology used was confusing (e.g. 
‘allocation of blindness’ and 
‘compliance with blindness’). The 
term ‘allocation concealment’ used in 
the context of observational studies is 
not appropriate 
Li et al. [15] Study eligibility criterion: only those studies with 
verified compliance. Newcastle-Ottawa checklist 
[21] for cohort studies 
Findings presented No  
Pusch et al. [12] None N/A N/A  
Sofi et al. [14] Study eligibility criterion: prospective study 
design 
N/A N/A  
Snoep et al. [13] Quality criteria relating to: control for 
confounders, measurement of exposure, 
completeness of follow-up and blinding, and, for 
case–control studies, matching and case definition 
No No  
Wisman et al. [16] Modified QUADAS tool [19] (for quality 
assessment of diagnostic accuracy studies). 11 
items assessed 
Findings presented Sensitivity analysis. Studies scoring ‘low risk 
of bias’ on eight or more of the quality items 
were considered to be good quality 
 
Prognostic studies may be of varying study design, e.g. cohort or case–control design, or one 
arm of an RCT, and may include a diagnostic test (such as a PFT) for identifying prognostic 
factors, and this is reflected in the choice of different quality assessment tools. Two of the 
reviews (Wisman et al. [16] and the HTA report [8]) modified one or more checklists to 
include items relevant to the particular topic area. The HTA report based quality assessment 
on QUADAS (quality assessment of diagnostic accuracy studies) [19] for assessing quality of 
test accuracy studies and guidelines for appraising prognostic studies [20], the latter of which 
has since been further developed into the Quality in Prognosis Study (QUIPS) tool [22]. It is 
important that quality assessment focuses on those aspects relevant to the prognosis question 
rather than be (solely) led by the study design, particularly where the prognostic aspect may 
not have been the main or only focus of the study. 
Presentation of results 
Primary studies mainly reported results as dichotomous frequency data, i.e. the number of 
clinical events in ‘aspirin resistant’ (prognostic factor positive) and ‘aspirin sensitive’ 
(prognostic factor negative) arms, where a threshold value was used to define the two groups. 
Fewer studies reported adjusted/unadjusted odds ratios (OR) and/or hazard ratios (HR). The 
extent to which data was transformed for use in meta-analysis (or presentation in forest plots) 
was variable across reviews. All reviews calculated RRs or ORs from frequency data. The 
test results for the prognostic factor were in the form of continuous data (i.e. level of platelet 
aggregation), but these were frequently dichotomised into positive/negative using a threshold, 
or presented as tertiles or quartiles. There was often no explanation regarding the choice of 
threshold. 
The HTA report [8] presented results for multiple (PFT) thresholds for designating ‘aspirin 
resistance’ (presence of prognostic factor) where reported; calculated thresholds where PFT 
test results were reported as tertiles or quartiles by collapsing these into two groups: 
presented HRs where available and presented adjusted results where available. Adjusted 
results can reveal whether a test has prognostic utility over and above other prognostic 
factors. None of the included studies reported prognostic models for individual risk 
prediction (i.e. a model containing PFT results and other prognostic factors for absolute risk 
prediction), so findings were limited to an average association between the prognostic factor 
and outcome. Few systematic reviews considered adjusted results or the potential importance 
of models. 
Time-to-event analyses may be more appropriate when accounting for different lengths of 
follow-up; HRs were presented in the HTA report [8], which also calculated HRs from other 
available data where possible (using methods described by Parmar et al. [23] and Perneger 
[24]). In contrast, two of the other reviews (Li et al. [15], Sofi et al. [14]) converted HRs to 
relative risks (RR) for inclusion in synthesis using meta-analysis. There is a balance between 
maximising data for analyses (improving effect estimates) and the assumptions that have to 
be made in order to do this (limiting conclusions that can be drawn). Presenting the same data 
using as many outcome statistics as reported or calculable does allow exploration of whether 
results are sensitive to the choice of outcome statistic. 
Five reviews undertook meta-analyses on variously defined composite cardiovascular 
outcomes (major adverse cardiac events (MACE)) [15], composite cardiovascular endpoints 
[16], clinical ischaemic events [13] or any cardiovascular events [11,14]) while only one [13] 
also presented individual outcomes (re-occlusion and myonecrosis after PCI) (fixed or 
random effects assumptions were used and a pooled RR or OR presented (see Table 3). All 
main analyses included all studies despite evidence of moderate to substantial statistical 
heterogeneity [25] for three (I2 values of 31% [15], 49% [13], 63% [14], 69% [11] and 77% 
[16]). This may be problematic when trying to draw conclusions for a particular method 
(PFT) for determining the prognostic factor, patient type or outcome; moreover, including 
large numbers of studies in a meta-analysis may lend a spurious robustness to the overall 
pooled estimate but do little in terms of informing clinical decisions due to large 
inconsistencies (heterogeneity). All five reviews considered heterogeneity using a number of 
different approaches; the most common was sub-grouping by PFT with some reviews also 
considering outcome, patient characteristics or type of antiplatelet therapy (mono or dual). 
One review [15] attempted to limit heterogeneity a priori by having more stringent inclusion 
criteria but did not sub-group by type of PFT. Having to deal with heterogeneity is not unique 
to prognostic research, but an added layer of heterogeneity may have to be considered as 
prognostic factors could be measured in multiple ways, using multiple thresholds, at multiple 
time-points and adjusted for differing sets of other prognostic factors. Using a fixed effects 
model may be particularly problematic for prognosis studies given the issues around 
heterogeneity, and its use in two reviews [11,15] was probably not justified. There is a danger 
that without careful consideration of heterogeneity, pooled estimates may give an impression 
of precision and certainty that is not justified. 
Table 3 Approaches to analysis 
Results reported Canivano and Gracia [10] HTA report [8] Li et al. [15] Krasopoulos at al. [11] Pusch et al. [12] Snoep et al. [13] Sofi et al. [14] Wisman et al. [16] 
Narrative/results tabulated only 
✓ 
   
✓ 
   
Tabulated by PFT     
✓ 
   
Forest plot (no pooling)  
✓ 
      
Meta-analysis (fixed effect)   
✓ ✓ 
    
Meta-analysis (random effects)   
✓ (As sensitivity analysis)   ✓ ✓ ✓ 
Pooled RR   
✓ (As sensitivity analysis)    ✓ ✓ 
Pooled OR   
✓ ✓ 
 
✓ 
  
HRs reported  
✓ (Not pooled)       
Meta-analysis by PFT    
✓ (For some)   ✓ ✓ 
Meta-analysis by outcome    
✓ 
 
✓ 
 
✓ 
Meta-analysis by mono- or dual 
therapy 
   
✓ 
   
✓ 
Meta-analysis by duration of  
follow-up 
      
✓ ✓ 
Meta-analysis by aspirin dose    
✓ 
 
✓ ✓ ✓ 
Meta-analysis by population       
✓ ✓ 
Sensitivity analysis (quality)        
✓ 
Results by different thresholds 
presented 
 
✓ 
      
Adjusted/unadjusted results presented  
✓ 
      
Discussion 
Systematic reviews of potential prognostic factors are on the increase, not least due to the 
rising interest in personalised medicine. Some guidance on how best to conduct such reviews 
exist [4-6] but is still evolving, and it is apparent that recommendations have not yet been 
widely adopted by systematic review authors. It is hoped that considerations presented in this 
article will further inform and extend what could constitute ‘good practice’ in systematic 
reviews of prognostic factors. Key considerations are summarised in Table 4. 
Table 4 Considerations when undertaking systematic reviews of prognostic factors 
Considerations Description 
Primary study identification Studies are not necessarily ‘badged’ as prognostic/predictive and a variety of terms are 
inconsistently used (e.g. risk, association, relationship etc.) 
Using prognostic filters substantially reduces the volume of search hits, but it is likely 
that relevant studies will be missed 
Study selection Selection criteria are not consistently reported. This may be particularly important in 
terms of specifying study design (retrospective/prospective) 
Hierarchy of studies Where large numbers of (poor quality) primary studies are identified, a step-wise 
approach to inclusion may be feasible: (i) inclusion only of studies reporting a 
prognostic model/ results adjusted for other prognostic factors, (ii) inclusion of 
prospective studies reporting on a single prognostic factor and (iii) inclusion of all 
studies reporting on a single prognostic factor 
Definition of prognostic factor If identifying a potential prognostic factor is dependent on a diagnostic test, then 
diagnostic accuracy aspects of one or more tests may need to be assessed in a separate 
exercise (the QUADAS tool [19] may be appropriate for this) 
Consider whether it is clinically appropriate to dichotomise prognostic factor or 
whether it should be used as a continuous variable (particularly in a model) 
Quality assessment The QUIPS tool [22] should be used to inform quality assessment rather than tools 
relating to specific study design; further tailoring may be necessary depending on topic 
specific issues 
Analysis Meta-analysis should only be undertaken after extensive consideration of clinical and 
methodological heterogeneity 
Data for meta-analysis can potentially be maximised by converting outcome statistics, 
which may also allow exploration of sensitivity of results to use of statistics 
Meta-analysis results should be made specific to particular threshold values or ideally 
for the factor left on its continuous scale 
Adjusted results should be presented where possible 
Time-to-event analyses should be considered when accounting for different lengths of 
follow-up 
Small study effects (potential publication bias) should be examined in those meta-
analyses containing ten or more studies 
Models based on individual patient data should be considered 
Identifying all relevant prognostic studies for inclusion into a systematic review is a time-
consuming process. The search strategy, including the type of study sought, should be guided 
by the review question, and there may be important differences depending on whether 
evidence is sought on one, or several, known or potential prognostic factors, one or more 
outcomes associated with those factors, and whether the question is related to proof of 
concept, prospective clinical validation, incremental predictive value or clinical utility [26]. 
It is known that published prognosis search filters have lower sensitivity and precision values 
than filters used for effectiveness questions [27], probably a result of variable terminology 
used in primary studies and a lack of consistent indexing. In this example, the research 
question of relevant primary studies was variously described as ‘aspirin resistance associated 
with clinical events’ [28], ‘…to determine the event rate in aspirin responders and non-
responders’ [29], ‘the role of aspirin resistance on outcome’ [30] and other variations. 
Certainly, it appears (from this example) that some studies are more likely to be identified 
than others, thus potentially weighting the evidence base in their favour, particularly where 
several reviews have been undertaken. 
Whilst very broad search strategies are likely to identify more relevant studies, screening 
studies can be very time consuming. Approaches such as ‘snowballing’/‘pearl growing’ [31] 
have been used in searches for the effectiveness of complex interventions and in qualitative 
research. Including such approaches may add value, but their usefulness has not yet been 
evaluated for prognosis searches and may not be applicable to all cases. Further, the aim of 
the primary studies may not be the same of the systematic review, particularly where 
prognostic utility is a secondary outcome; it may thus not be immediately obvious that 
primary studies contain relevant information and a wider and more thorough assessment for 
study selection is likely to be required. 
As a consequence of the difficulties in identifying relevant studies, there is variable inclusion 
of studies into systematic reviews or other evidence summaries. Added to this are varying 
approaches to analyses and dealing with heterogeneity, which has resulted in meta-analyses 
(where performed) obtaining different effect estimates and confidence intervals, using 
different types of outcome statistics and pooling studies with varying levels of heterogeneity. 
This has implications where a single systematic review, or even a sub-set of reviews, is being 
used to inform clinical opinion. 
It is apparent that approaches to quality assessment have developed over time, with more 
recent systematic reviews [32,33] using tools such as QUIPS. A degree of tailoring to the 
specific topic is likely to be appropriate, for example, if there are known confounders (in this 
area one of the main potential confounders was compliance). Only two of the eight 
systematic reviews used quality assessment to inform the discussion around their findings, 
which suggests that the importance of quality assessment is not being sufficiently recognised. 
Whilst this article explored how primary studies were quality assessed in the individual 
systematic reviews, the overall quality of the reviews was not formally assessed. There is 
currently no validated tool for assessing the quality of a systematic review of prognostic 
studies specifically; it is the intention of ROBIS [34], a new quality assessment tool under 
development, to be adaptable to systematic reviews of studies of different designs. An 
adapted GRADE framework [35] has also recently been proposed for use in conducting 
systematic review of prognostic factor research, which may improve the reporting and/or 
conduct of systematic reviews in this area. 
Both quality assessment and interpretation of findings of prognostic studies are more 
complex where the identification of a prognostic factor is dependent on one or more 
diagnostic tests, with associated test accuracy issues. There is an additional layer of 
complexity where the potential prognostic factor is one of several, and is linked to several 
outcomes, as was the case in this example. As discussed in Dahlen et al. [36], it is not 
sufficient to demonstrate that there is a statistically significant association between a test 
result and a given outcome, as this may not be clinically useful. 
  
Adjusted results show the incremental value of adding a (new) prognostic factor to existing 
ones for predicting an individual’s future risk [37]. The prognostic value is best examined on 
its continuous scale rather than dichotomising (e.g. actual blood pressure measurement rather 
than ‘high’ or ‘normal’ blood pressure), as this is more powerful and avoids arbitrary cut-off 
points. Therefore, where the prognostic question is complex and the reporting and quality of 
primary studies is poor, it is worth considering whether all primary studies need to be 
reviewed in detail, or whether it may be sufficient to examine those reporting adjusted results 
(from regression modelling). Studies presenting only unadjusted results may be of limited 
value and could be restricted to those deemed to be of higher quality (e.g. prospective study 
design), though reporting is likely to be an issue. 
Some primary studies may report prognostic models, where the impact of adding the potential 
factor of interest to a model is explored, and an individual’s risk can be determined, as 
opposed to an average risk. However, different approaches to building models may hamper 
synthesis of results across (model based) studies, so including such studies in a systematic 
review is not without difficulties. It is unlikely that model-based studies will be available for 
all questions of interest; none were included in any of the reviews assessed in this article. 
Where individual participant data (IPD) is available for analysis, this could negate some of 
the issues affecting the conclusions of such a review. IPD allows analyses based on the raw 
data from all studies, as opposed to aggregate (study) level data, and as such provides greater 
power to detect any prognostic effect. With available IPD, re-analysis could be performed to 
ensure that all studies provided the same effectiveness statistics. The impact of heterogeneity 
could be explored by analyses excluding subsets of patients, for example a particular trial 
using a different study design. Using IPD may also allow for the investigation of adjusted 
prognostic effects, which, as discussed, could provide a greater estimate of the true 
prognostic value of factors of interest. Using IPD data is however a resource-intensive and 
methodologically challenging process, and problems around availability bias, poor reporting 
and heterogeneity may not be overcome [38,39]. 
We acknowledge that using our own systematic review as one of the example reviews may 
entail an inherent bias. This is a very recent review, and thus it may have been easier to 
incorporate more recent recommendations. The aim of this article was not to critique 
individual reviews but to identify common areas with potential for methodological 
development. Further, only one clinical area/question has been considered as an example in 
this article. It is hoped that the considerations outlined in Table 4 will add to the growing 
body of methodological recommendations in this field and aid those both using and 
undertaking systematic reviews of prognostic questions. This in turn may lead to better 
research recommendations and more robust primary studies. There are some similarities 
between our considerations and those identified in another clinical area (low back pain [4]), 
and this suggests generalizability to further clinical areas—indeed, similar methodological 
issues are currently being encountered in an ongoing systematic review [40] of prognostic 
factors and prognostic models for the recurrence of venous thromboembolism (VTE) 
following treatment for a first idiopathic VTE. There are also some more specific 
recommendations, e.g. around defining the prognostic factor, and approaches to analysis and 
study inclusion that have not previously been addressed. 
  
Poorly conducted and reported primary prognostic research continues to hamper the potential 
of systematic reviews to inform on clinical questions. However, well-conducted reviews, 
which highlight uncertainty and heterogeneity in primary research, will be able to inform 
future primary studies. The utility of conducting further primary studies on individual 
prognostic factors should however also be considered; it may be more appropriate to focus on 
model-based studies, potentially using IPD data. 
Conclusions 
Systematic reviews of prognostic factors are hampered by poor reporting of primary research 
[41], and the ability of systematic reviews of prognostic factors to inform on clinical 
questions is complicated by the utilisation of different methodological approaches. 
Differences in approaches to study selection, synthesis and presentation of results may have 
the potential to influence the overall findings, which in turn may have implications for 
clinical decision-making, particularly where clinical opinion is being informed by a single 
systematic review. 
Conclusions may be influenced by an overall effect size (and precision) where meta-analysis 
has been undertaken and by the interpretation of findings (e.g. extent of caveats applied). The 
potential for bias to be introduced into analyses through attempting to maximise data by 
making strong assumptions can also be significant. As with all evidence synthesis, 
inconsistency in the evidence must be accounted for in the careful interpretation of results. A 
hierarchy of evidence should be considered with adjusted results providing the greatest 
evidence for true prognostic value. 
The findings from this article, based on a review of systematic reviews in one clinical area, 
have been used to generate a number of recommendations for those undertaking systematic 
reviews of prognostic research. These include a step-wise hierarchical approach to study 
selection and suggested approaches to searching, defining the prognostic factor, quality 
assessment and analysis, particularly with regard to consideration of heterogeneity. 
This work adds to and extends the growing body of methodological evidence in this field and 
may ultimately help to inform the debate about what constitutes good systematic review 
practice for questions of prognostic utility. 
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